For: | Ateş F, Yalnız M, Alan S. Impact of liver steatosis on response to pegylated interferon therapy in patients with chronic hepatitis B. World J Gastroenterol 2011; 17(40): 4517-4522 [PMID: 22110283 DOI: 10.3748/wjg.v17.i40.4517] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v17/i40/4517.htm |
Number | Citing Articles |
1 |
Raluca Pais, Elena Rusu, Vlad Ratziu. The Impact of Obesity and Metabolic Syndrome on Chronic Hepatitis B and Drug-Induced Liver Disease. Clinics in Liver Disease 2014; 18(1): 165 doi: 10.1016/j.cld.2013.09.015
|
2 |
Yuting Diao, Juan Tang, Xuerong Wang, Wei Deng, Jing Tang, Chunfang You. Metabolic Syndrome, Nonalcoholic Fatty Liver Disease, and Chronic Hepatitis B: A Narrative Review. Infectious Diseases and Therapy 2023; 12(1): 53 doi: 10.1007/s40121-022-00725-6
|
3 |
Jianbin Zhang, Shuangzhe Lin, Daixi Jiang, Mengting Li, Yuanwen Chen, Jun Li, Jiangao Fan. Chronic hepatitis B and non‐alcoholic fatty liver disease: Conspirators or competitors?. Liver International 2020; 40(3): 496 doi: 10.1111/liv.14369
|
4 |
L. Gong, J. Liu, J. Wang, G.Q. Lou, J.P. Shi. Hepatic Steatosis as a Predictive Factor of Antiviral Effect of Pegylated Interferon Therapy in Patients With Hepatitis B. Transplantation Proceedings 2015; 47(10): 2886 doi: 10.1016/j.transproceed.2015.10.023
|
5 |
博诗 陈. Interaction and Possible Mechanism between Non-Alcoholic Fatty Liver Disease and Chronic Hepatitis B. Advances in Clinical Medicine 2022; 12(11): 10453 doi: 10.12677/ACM.2022.12111506
|
6 |
Qingling Chen, Lili Zhao, Ling Mei, Rui Zhong, Ping Han, Hang Yang, Qian Li, Jia Li. Association of sex hormones with hepatic steatosis in men with chronic hepatitis B. Digestive and Liver Disease 2022; 54(3): 378 doi: 10.1016/j.dld.2021.05.022
|
7 |
Ming Yang, Lai Wei. Impact of NAFLD on the outcome of patients with chronic hepatitis B in Asia. Liver International 2022; 42(9): 1981 doi: 10.1111/liv.15252
|
8 |
Jiayi Wang, Lingyao Du, Hong Tang. Suppression of Interferon-α Treatment Response by Host Negative Factors in Hepatitis B Virus Infection. Frontiers in Medicine 2021; 8 doi: 10.3389/fmed.2021.784172
|
9 |
J. C. Hsiang, G. L.‐H. Wong, H. L.‐Y. Chan, A. W.‐H. Chan, A. M.‐L. Chim, V. W.‐S. Wong. Metabolic syndrome delays HBeAg seroclearance in Chinese patients with hepatitis B. Alimentary Pharmacology & Therapeutics 2014; 40(6): 716 doi: 10.1111/apt.12874
|
10 |
Mariana Verdelho Machado. Controlled Attenuation Parameter as a Noninvasive Method to Detect and Quantify Hepatic Steatosis in Chronic Liver Disease: What Is the Clinical Relevance. GE - Portuguese Journal of Gastroenterology 2017; 24(4): 157 doi: 10.1159/000478944
|
11 |
|
12 |
Mauro Viganò, Luca Valenti, Pietro Lampertico, Floriana Facchetti, Benedetta Maria Motta, Roberta D'Ambrosio, Solange Romagnoli, Paola Dongiovanni, Benedetta Donati, Silvia Fargion, Massimo Colombo. Patatin-like phospholipase domain-containing 3 I148M affects liver steatosis in patients with chronic hepatitis B. Hepatology 2013; 58(4): 1245 doi: 10.1002/hep.26445
|
13 |
Qi Zheng, Biyao Zou, Yuankai Wu, Yeehui Yeo, Huizhen Wu, Christopher D Stave, Ramsey C. Cheung, Mindie H. Nguyen. Systematic review with meta‐analysis: prevalence of hepatic steatosis, fibrosis and associated factors in chronic hepatitis B. Alimentary Pharmacology & Therapeutics 2021; 54(9): 1100 doi: 10.1111/apt.16595
|
14 |
Yu-Qiang Mi, Qi-Yu Shi, Liang Xu, Rui-Fang Shi, Yong-Gang Liu, Ping Li, Feng Shen, Wei Lu, Jian-Gao Fan. Controlled Attenuation Parameter for Noninvasive Assessment of Hepatic Steatosis Using Fibroscan®: Validation in Chronic Hepatitis B. Digestive Diseases and Sciences 2015; 60(1): 243 doi: 10.1007/s10620-014-3341-x
|
15 |
Yuki Haga, Tatsuo Kanda, Reina Sasaki, Masato Nakamura, Shingo Nakamoto, Osamu Yokosuka. Nonalcoholic fatty liver disease and hepatic cirrhosis: Comparison with viral hepatitis-associated steatosis. World Journal of Gastroenterology 2015; 21(46): 12989-12995 doi: 10.3748/wjg.v21.i46.12989
|
16 |
Jing Chen, Meng-Lan Wang, Qin Long, Lang Bai, Hong Tang. High value of controlled attenuation parameter predicts a poor antiviral response in patients with chronic hepatits B. Hepatobiliary & Pancreatic Diseases International 2017; 16(4): 370 doi: 10.1016/S1499-3872(16)60144-3
|
17 |
Lili Wu, Zhihui Li, Na Gao, Hong Deng, Qiyi Zhao, Zhaoxia Hu, Junfeng Chen, Ziying Lei, Jinhua Zhao, Bingliang Lin, Zhiliang Gao. Interferon-α could induce liver steatosis to promote HBsAg loss by increasing triglyceride level. Heliyon 2024; 10(12): e32730 doi: 10.1016/j.heliyon.2024.e32730
|
18 |
Hongjie Ou, Shaohang Cai, Ying Liu, Muye Xia, Jie Peng. A noninvasive diagnostic model to assess nonalcoholic hepatic steatosis in patients with chronic hepatitis B. Therapeutic Advances in Gastroenterology 2017; 10(2): 207 doi: 10.1177/1756283X16681707
|
19 |
Yongfen Zhu, Qiao Yang, Fangfang Lv, Yunsong Yu. The Effect of Hepatosteatosis on Response to Antiviral Treatment in Patients with Chronic Hepatitis B: A Meta-Analysis. Gastroenterology Research and Practice 2017; 2017: 1 doi: 10.1155/2017/1096406
|
20 |
Jin Won Chang, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Seung Up Kim. Hepatic Steatosis Index in the Detection of Fatty Liver in Patients with Chronic Hepatitis B Receiving Antiviral Therapy. Gut and Liver 2021; 15(1): 117 doi: 10.5009/gnl19301
|
21 |
Rajneesh Kumar, George Boon-Bee Goh. Chronic hepatitis B and fatty liver: Issues in clinical management. Clinics and Research in Hepatology and Gastroenterology 2016; 40(6): 755 doi: 10.1016/j.clinre.2015.12.011
|
22 |
Shi-Yi Liu, Dian Wang, Jing Liu, Lu-Ping Yang, Gong-Ying Chen. Influence of nonalcoholic fatty liver disease on response to antiviral treatment in patients with chronic hepatitis B: A meta-analysis. World Journal of Hepatology 2024; 16(3): 465-476 doi: 10.4254/wjh.v16.i3.465
|
23 |
Vahdat Poortahmasebi, Seyed Moayed Alavian, Hossein Keyvani, Mehdi Norouzi, Mahmood Mahmoodi, Seyed Mohammad Jazayeri. Hepatic Steatosis: Prevalence and Host/Viral Risk Factors in Iranian Patients with Chronic Hepatitis B Infection. Asian Pacific Journal of Cancer Prevention 2014; 15(9): 3879 doi: 10.7314/APJCP.2014.15.9.3879
|
24 |
Hira Hanif, Muzammil M. Khan, Mukarram J. Ali, Pir A. Shah, Jinendra Satiya, Daryl T.Y. Lau, Aysha Aslam. A New Endemic of Concomitant Nonalcoholic Fatty Liver Disease and Chronic Hepatitis B. Microorganisms 2020; 8(10): 1526 doi: 10.3390/microorganisms8101526
|
25 |
Anthony W.H. Chan, Grace L.H. Wong, Vincent W.S. Wong. Impact of Non-alcoholic Fatty Liver Disease on Chronic Hepatitis B Infection. Current Hepatology Reports 2017; 16(2): 97 doi: 10.1007/s11901-017-0340-3
|
26 |
Jin Won Chang, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Seung Up Kim. No influence of hepatic steatosis on the 3‐year outcomes of patients with quiescent chronic hepatitis B. Journal of Viral Hepatitis 2021; 28(11): 1545 doi: 10.1111/jvh.13594
|
27 |
Manoj Kumar, Archana Rastogi, Tarandeep Singh, Chhagan Behari, Ekta Gupta, Hitendra Garg, Ramesh Kumar, Vikram Bhatia, Shiv K Sarin. Controlled attenuation parameter for non‐invasive assessment of hepatic steatosis: Does etiology affect performance?. Journal of Gastroenterology and Hepatology 2013; 28(7): 1194 doi: 10.1111/jgh.12134
|
28 |
Jing-Houng Wang, Chao-Hung Hung, Fang-Ying Kuo, Hock-Liew Eng, Chien-Hung Chen, Chun-Mo Lee, Sheng-Nan Lu, Tsung-Hui Hu. Ultrasonographic Quantification of Hepatic–Renal Echogenicity Difference in Hepatic Steatosis Diagnosis. Digestive Diseases and Sciences 2013; 58(10): 2993 doi: 10.1007/s10620-013-2769-8
|
29 |
景楠 鲁. Comparison of Non-Invasive Diagnostic Tools for Steatosis of Chronic Hepatitis B. Advances in Clinical Medicine 2023; 13(07): 10904 doi: 10.12677/ACM.2023.1371522
|
30 |
Ana C. Cardoso, Michel Beaugrand, Victor de Ledinghen, Catherine Douvin, Raoul Poupon, Jean-Claude Trinchet, Marianne Ziol, Pierre Bedossa, Patrick Marcellin. Diagnostic performance of controlled attenuation parameter for predicting steatosis grade in chronic hepatitis B. Annals of Hepatology 2015; 14(6): 826 doi: 10.5604/16652681.1171762
|
31 |
Jie Li, An K. Le, Kevin T. Chaung, Linda Henry, Joseph K. Hoang, Ramsey Cheung, Mindie H. Nguyen. Fatty liver is not independently associated with the rates of complete response to oral antiviral therapy in chronic hepatitis B patients. Liver International 2020; 40(5): 1052 doi: 10.1111/liv.14415
|
32 |
Danqing Hu, Hongwu Wang, Hai Wang, Yaqi Wang, Xiaoyang Wan, Weiming Yan, Xiaoping Luo, Qin Ning. Non-alcoholic hepatic steatosis attenuates hepatitis B virus replication in an HBV-immunocompetent mouse model. Hepatology International 2018; 12(5): 438 doi: 10.1007/s12072-018-9877-7
|
33 |
Ming-Lun Yeh, Jee-Fu Huang, Ming-Lung Yu. Metabolic Steatotic Liver Disease. 2024; : 261 doi: 10.1016/B978-0-323-99649-5.00008-X
|
34 |
Yi-Cheng Chen, Wen-Juei Jeng, Chao-Wei Hsu, Chun-Yen Lin. Impact of hepatic steatosis on treatment response in nuclesos(t)ide analogue-treated HBeAg-positive chronic hepatitis B: a retrospective study. BMC Gastroenterology 2020; 20(1) doi: 10.1186/s12876-020-01289-w
|
35 |
Jan-Hendrik Bockmann, Matin Kohsar, John M. Murray, Vanessa Hamed, Maura Dandri, Stefan Lüth, Ansgar W. Lohse, Julian Schulze-zur-Wiesch. High Rates of Liver Cirrhosis and Hepatocellular Carcinoma in Chronic Hepatitis B Patients with Metabolic and Cardiovascular Comorbidities. Microorganisms 2021; 9(5): 968 doi: 10.3390/microorganisms9050968
|
36 |
Liang Xu, Wei Lu, Ping Li, Feng Shen, Yu-Qiang Mi, Jian-Gao Fan. A comparison of hepatic steatosis index, controlled attenuation parameter and ultrasound as noninvasive diagnostic tools for steatosis in chronic hepatitis B. Digestive and Liver Disease 2017; 49(8): 910 doi: 10.1016/j.dld.2017.03.013
|